{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:52:50Z","timestamp":1793994770754,"version":"4.8.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40120-026-00948-6","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T18:40:38Z","timestamp":1778179238000},"page":"1743-1762","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Real-World Safety and Effectiveness of 24-Hour Foslevodopa\/Foscarbidopa in Parkinson's Disease: ROSSINI Study 6-Month Interim Results"],"prefix":"10.1007","volume":"15","author":[{"given":"Wolfgang H.","family":"Jost","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3437-0267","authenticated-orcid":false,"given":"Filip","family":"Bergquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Hassin-Baer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6369-1203","authenticated-orcid":false,"given":"Robert A.","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tove","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene A.","family":"Malaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago A.","family":"Mestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Schwingenschuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Simu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa T.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Caughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallika","family":"Gopalkrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavnit","family":"Kukreja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"O\u2019Meara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megha B.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Aldred","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"948_CR1","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00702-025-02893-4","volume":"132","author":"P Riederer","year":"2025","unstructured":"Riederer P, Strobel S, Nagatsu T, Watanabe H, Chen X, L\u00f6schmann P-A, et al. Levodopa treatment: impacts and mechanisms throughout Parkinson\u2019s disease progression. J Neural Transm. 2025;132:743\u201379. https:\/\/doi.org\/10.1007\/s00702-025-02893-4.","journal-title":"J Neural Transm"},{"key":"948_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/mds.26082","volume":"30","author":"PA LeWitt","year":"2015","unstructured":"LeWitt PA. Levodopa therapy for Parkinson\u2019s disease: pharmacokinetics and pharmacodynamics. Mov Disord. 2015;30:64\u201372. https:\/\/doi.org\/10.1002\/mds.26082.","journal-title":"Mov Disord"},{"key":"948_CR3","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s00702-024-02773-3","volume":"131","author":"N Schr\u00f6ter","year":"2024","unstructured":"Schr\u00f6ter N, Sajonz BEA, Jost WH, Rijntjes M, Coenen VA, Groppa S. Advanced therapies in Parkinson\u2019s disease: an individualized approach to their indication. J Neural Transm. 2024;131:1285\u201393. https:\/\/doi.org\/10.1007\/s00702-024-02773-3.","journal-title":"J Neural Transm"},{"key":"948_CR4","doi-asserted-by":"publisher","first-page":"S141","DOI":"10.3233\/jpd-212650","volume":"11","author":"S Mathur","year":"2021","unstructured":"Mathur S, Stamford J. Bringing advanced therapies for Parkinson\u2019s disease to the clinic: the patient\u2019s perspective. J Parkinsons Dis. 2021;11:S141\u20135. https:\/\/doi.org\/10.3233\/jpd-212650.","journal-title":"J Parkinsons Dis"},{"key":"948_CR5","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.3233\/jpd-212813","volume":"11","author":"M Rosebraugh","year":"2021","unstructured":"Rosebraugh M, Liu W, Neenan M, Facheris MF. Foslevodopa\/Foscarbidopa is well tolerated and maintains stable levodopa and carbidopa exposure following subcutaneous infusion. J Parkinsons Dis. 2021;11:1695\u2013702. https:\/\/doi.org\/10.3233\/jpd-212813.","journal-title":"J Parkinsons Dis"},{"key":"948_CR6","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/s1474-4422(22)00400-8","volume":"21","author":"MJ Soileau","year":"2022","unstructured":"Soileau MJ, Aldred J, Budur K, Fisseha N, Fung VS, Jeong A, et al. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson\u2019s disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol. 2022;21:1099\u2013109. https:\/\/doi.org\/10.1016\/s1474-4422(22)00400-8.","journal-title":"Lancet Neurol"},{"key":"948_CR7","unstructured":"Hauser R, Fung V, Kimber T, Klos K, Facheris M, Jeong A, et al. Long-Term Safety and Efficacy of Foscarbidopa\/Foslevodopa in Patients with Advanced Parkinson\u2019s Disease: Results From an Ongoing Phase 3 Open-Label Extension with Up to 1 Year Follow-Up [Internet]. 2024 [cited 2025 July 16]. https:\/\/www.mdsabstracts.org\/abstract\/long-term-safety-and-efficacy-of-foscarbidopa-foslevodopa-in-patients-with-advanced-parkinsons-disease-results-from-an-ongoing-phase-3-open-label-extension-with-up-to-1-year-follow-up\/. Accessed 16 July 2025"},{"key":"948_CR8","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000208722","author":"F Bergquist","year":"2025","unstructured":"Bergquist F, Aldred J, Danielsen E, Carroll C, Matthews C, Jia J, et al. Sustained long-term safety and tolerability of Foslevodopa\/Foscarbidopa in Parkinson\u2019s Disease: 96-week primary treatment period results from an ongoing open-label extension study (P11-5.006). Neurology. 2025. https:\/\/doi.org\/10.1212\/wnl.0000000000208722.","journal-title":"Neurology"},{"key":"948_CR9","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s40120-023-00533-1","volume":"12","author":"J Aldred","year":"2023","unstructured":"Aldred J, Freire-Alvarez E, Amelin AV, Antonini A, Bergmans B, Bergquist F, et al. Continuous subcutaneous Foslevodopa\/Foscarbidopa in Parkinson\u2019s disease: safety and efficacy results from a 12-month, single-arm, open-label, phase 3 study. Neurol Ther. 2023;12:1937\u201358. https:\/\/doi.org\/10.1007\/s40120-023-00533-1.","journal-title":"Neurol Ther"},{"key":"948_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/s1474-4422(13)70293-x","volume":"13","author":"CW Olanow","year":"2014","unstructured":"Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson\u2019s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13:141\u20139. https:\/\/doi.org\/10.1016\/s1474-4422(13)70293-x.","journal-title":"Lancet Neurol"},{"key":"948_CR11","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1002\/mdc3.13239","volume":"8","author":"DG Standaert","year":"2021","unstructured":"Standaert DG, Aldred J, Anca\u2010Herschkovitsch M, Bourgeois P, Cubo E, Davis TL, et al. DUOGLOBE: one\u2010year outcomes in a real\u2010world study of levodopa carbidopa intestinal gel for Parkinson\u2019s disease. Mov Disord Clin Pract. 2021;8:1061\u201374. https:\/\/doi.org\/10.1002\/mdc3.13239.","journal-title":"Mov Disord Clin Pract"},{"key":"948_CR12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3233\/jpd-191783","volume":"10","author":"UM Fietzek","year":"2019","unstructured":"Fietzek UM, Schulz SJ, Ziegler K, Ceballos-Baumann AO. The minimal clinically relevant change of the FOG score. J Parkinsons Dis. 2019;10:325\u201332. https:\/\/doi.org\/10.3233\/jpd-191783.","journal-title":"J Parkinsons Dis"},{"key":"948_CR13","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3233\/jpd-225105","volume":"13","author":"KR Chaudhuri","year":"2023","unstructured":"Chaudhuri KR, Kov\u00e1cs N, Pontieri FE, Aldred J, Bourgeois P, Davis TL, et al. Levodopa Carbidopa intestinal gel in advanced Parkinson\u2019s disease: DUOGLOBE final 3-year results. J Parkinsons Dis. 2023;13:769\u201383. https:\/\/doi.org\/10.3233\/jpd-225105.","journal-title":"J Parkinsons Dis"},{"key":"948_CR14","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s10072-019-03920-5","volume":"40","author":"E Olivola","year":"2019","unstructured":"Olivola E, Fasano A, Varanese S, Lena F, Santilli M, Femiano C, et al. Continuous subcutaneous apomorphine infusion in Parkinson\u2019s disease: causes of discontinuation and subsequent treatment strategies. Neurol Sci. 2019;40:1917\u201323. https:\/\/doi.org\/10.1007\/s10072-019-03920-5.","journal-title":"Neurol Sci"},{"key":"948_CR15","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1007\/s00415-017-8477-0","volume":"264","author":"\u00c1 Sesar","year":"2017","unstructured":"Sesar \u00c1, Fern\u00e1ndez-Pajar\u00edn G, Ares B, Rivas MT, Castro A. Continuous subcutaneous apomorphine infusion in advanced Parkinson\u2019s disease: 10-year experience with 230 patients. J Neurol. 2017;264:946\u201354. https:\/\/doi.org\/10.1007\/s00415-017-8477-0.","journal-title":"J Neurol"},{"key":"948_CR16","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1177\/1877718x241310727","volume":"15","author":"SH Isaacson","year":"2024","unstructured":"Isaacson SH, Espay AJ, Pahwa R, Agarwal P, Shill HA, Hui J, et al. Continuous, subcutaneous apomorphine infusion for Parkinson disease motor fluctuations: Results from the phase 3, long-term, open-label United States InfusON study. J Park\u2019s Dis. 2024;15:361\u201373. https:\/\/doi.org\/10.1177\/1877718x241310727.","journal-title":"J Park\u2019s Dis"},{"key":"948_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e8668","volume":"346","author":"ML Bell","year":"2013","unstructured":"Bell ML, Kenward MG, Fairclough DL, Horton NJ. Differential dropout and bias in randomised controlled trials: when it matters and when it may not. BMJ. 2013;346:e8668. https:\/\/doi.org\/10.1136\/bmj.e8668.","journal-title":"BMJ"},{"key":"948_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2025.107985","volume":"142","author":"P Solla","year":"2026","unstructured":"Solla P, Ercoli T. Early discontinuation and titration strategies in foslevodopa\/foscarbidopa therapy for Parkinson\u2019s disease. Parkinsonism Relat Disord. 2026;142:107985. https:\/\/doi.org\/10.1016\/j.parkreldis.2025.107985.","journal-title":"Parkinsonism Relat Disord"},{"key":"948_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/jep.12095","volume":"20","author":"K Ladova","year":"2014","unstructured":"Ladova K, Vlcek J, Vytrisalova M, Maly J. Healthy adherer effect \u2013 the pitfall in the interpretation of the effect of medication adherence on health outcomes. J Eval Clin Pract. 2014;20:111\u20136. https:\/\/doi.org\/10.1111\/jep.12095.","journal-title":"J Eval Clin Pract"},{"key":"948_CR20","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1002\/mds.22788","volume":"25","author":"M Menza","year":"2010","unstructured":"Menza M, Dobkin RD, Marin H, Bienfait K. Sleep disturbances in Parkinson\u2019s disease. Mov Disord. 2010;25:S117\u201322. https:\/\/doi.org\/10.1002\/mds.22788.","journal-title":"Mov Disord"},{"key":"948_CR21","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1007\/s13311-020-00938-y","volume":"17","author":"JRP Zuzu\u00e1rregui","year":"2020","unstructured":"Zuzu\u00e1rregui JRP, During EH. Sleep issues in Parkinson\u2019s disease and their management. Neurotherapeutics. 2020;17:1480\u201394. https:\/\/doi.org\/10.1007\/s13311-020-00938-y.","journal-title":"Neurotherapeutics"},{"key":"948_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2025.100334","volume":"12","author":"MD Smith","year":"2025","unstructured":"Smith MD, Cullen A, Portlock GE, Drake MJ, Ben-Shlomo Y, Henderson EJ. Nocturnal polyuria is common in Parkinson\u2019s and is associated with orthostatic hypotension. Clin Parkinsonism Relat Disord. 2025;12:100334. https:\/\/doi.org\/10.1016\/j.prdoa.2025.100334.","journal-title":"Clin Parkinsonism Relat Disord"},{"key":"948_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2025.100330","volume":"12","author":"KR Chaudhuri","year":"2025","unstructured":"Chaudhuri KR, Bouchard M, Freire-Alvarez E, Pahwa R, Bergmann L, Gupta R, et al. Post hoc exploratory analysis of the effect of foslevodopa\/foscarbidopa continuous subcutaneous infusion on nocturia in patients with Parkinson\u2019s disease. Clin Parkinsonism Relat Disord. 2025;12:100330. https:\/\/doi.org\/10.1016\/j.prdoa.2025.100330.","journal-title":"Clin Parkinsonism Relat Disord"},{"key":"948_CR24","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.3233\/jpd-202069","volume":"10","author":"C Buhmann","year":"2020","unstructured":"Buhmann C, Kassubek J, Jost WH. Management of pain in Parkinson\u2019s disease. J Parkinsons Dis. 2020;10:S37-48. https:\/\/doi.org\/10.3233\/jpd-202069.","journal-title":"J Parkinsons Dis"},{"key":"948_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.parkreldis.2010.08.012","volume":"17","author":"S-E Soh","year":"2011","unstructured":"Soh S-E, Morris ME, McGinley JL. Determinants of health-related quality of life in Parkinson\u2019s disease: a systematic review. Parkinsonism Relat Disord. 2011;17:1\u20139. https:\/\/doi.org\/10.1016\/j.parkreldis.2010.08.012.","journal-title":"Parkinsonism Relat Disord"},{"key":"948_CR26","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1002\/mds.26270","volume":"30","author":"KR Chaudhuri","year":"2015","unstructured":"Chaudhuri KR, Rizos A, Trenkwalder C, Rascol O, Pal S, Martino D, et al. King\u2019s Parkinson\u2019s disease pain scale, the first scale for pain in PD: an international validation. Mov Disord. 2015;30:1623\u201331. https:\/\/doi.org\/10.1002\/mds.26270.","journal-title":"Mov Disord"},{"key":"948_CR27","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1002\/mds.28703","volume":"36","author":"E Freire\u2010Alvarez","year":"2021","unstructured":"Freire\u2010Alvarez E, Kur\u010da E, Manzanares LL, Pekkonen E, Spanaki C, Vanni P, et al. Levodopa\u2010Carbidopa intestinal gel reduces dyskinesia in Parkinson\u2019s disease in a randomized trial. Mov Disord. 2021;36:2615\u201323. https:\/\/doi.org\/10.1002\/mds.28703.","journal-title":"Mov Disord"},{"key":"948_CR28","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s40120-024-00583-z","volume":"13","author":"E Freire-Alvarez","year":"2024","unstructured":"Freire-Alvarez E, Vanni P, Kur\u010da E, Lopez-Manzanares L, Kov\u00e1cs N, Spanaki C, et al. Dyskinesia and pain in advanced Parkinson\u2019s disease: post hoc analysis from the phase 3b, open-label, randomized DYSCOVER study. Neurol Ther. 2024;13:437\u201347. https:\/\/doi.org\/10.1007\/s40120-024-00583-z.","journal-title":"Neurol Ther"},{"key":"948_CR29","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/wco.0000000000000118","volume":"27","author":"JC Giugni","year":"2014","unstructured":"Giugni JC, Okun MS. Treatment of advanced Parkinson\u2019s disease. Curr Opin Neurol. 2014;27:450\u201360. https:\/\/doi.org\/10.1097\/wco.0000000000000118.","journal-title":"Curr Opin Neurol"},{"key":"948_CR30","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1002\/mds.29878","volume":"39","author":"C Brefel\u2010Courbon","year":"2024","unstructured":"Brefel\u2010Courbon C, Harroch E, Marques A, Devos D, Thalamas C, Rousseau V, et al. Oxycodone or higher dose of Levodopa for the treatment of Parkinsonian central pain: OXYDOPA trial. Mov Disord. 2024;39:1533\u201343. https:\/\/doi.org\/10.1002\/mds.29878.","journal-title":"Mov Disord"},{"key":"948_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2023.122696","volume":"455","author":"S Bandrivska","year":"2023","unstructured":"Bandrivska S, Bandrivskyi M, Lonergan B, Ciocca M, Tai Y, Slobodin T. Peripheral neuropathy in Parkinson\u2019s disease: association between levodopa treatment and vitamin deficiency. J Neurol Sci. 2023;455:122696. https:\/\/doi.org\/10.1016\/j.jns.2023.122696.","journal-title":"J Neurol Sci"},{"key":"948_CR32","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1007\/s00702-024-02769-z","volume":"131","author":"A Rekik","year":"2024","unstructured":"Rekik A, Santoro C, Poplawska-Domaszewicz K, Qamar MA, Batzu L, Landolfo S, et al. Parkinson\u2019s disease and vitamins: a focus on vitamin B12. J Neural Transm. 2024;131:1495\u2013509. https:\/\/doi.org\/10.1007\/s00702-024-02769-z.","journal-title":"J Neural Transm"},{"key":"948_CR33","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1002\/mds.21667","volume":"23","author":"S Rahman","year":"2008","unstructured":"Rahman S, Griffin HJ, Quinn NP, Jahanshahi M. Quality of life in Parkinson\u2019s Disease: the relative importance of the symptoms. Mov Disord. 2008;23:1428\u201334. https:\/\/doi.org\/10.1002\/mds.21667.","journal-title":"Mov Disord"},{"key":"948_CR34","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1002\/mds.28675","volume":"36","author":"M Camacho","year":"2021","unstructured":"Camacho M, Greenland JC, Williams\u2010Gray CH. The gastrointestinal dysfunction scale for Parkinson\u2019s Disease. Mov Disord. 2021;36:2358\u201366. https:\/\/doi.org\/10.1002\/mds.28675.","journal-title":"Mov Disord"},{"key":"948_CR35","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1007\/s00415-022-11546-5","volume":"270","author":"P Martinez-Martin","year":"2023","unstructured":"Martinez-Martin P, Skorvanek M, Henriksen T, Lindvall S, Domingos J, Alobaidi A, et al. Impact of advanced Parkinson\u2019s Disease on caregivers: an international real-world study. J Neurol. 2023;270:2162\u201373. https:\/\/doi.org\/10.1007\/s00415-022-11546-5.","journal-title":"J Neurol"},{"key":"948_CR36","doi-asserted-by":"publisher","first-page":"10","DOI":"10.18773\/austprescr.003","volume":"48","author":"N Mouchaileh","year":"2025","unstructured":"Mouchaileh N, Cameron J. Device-assisted therapies for Parkinson disease. Aust Prescr. 2025;48:10\u20137. https:\/\/doi.org\/10.18773\/austprescr.003.","journal-title":"Aust Prescr"},{"key":"948_CR37","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1016\/j.parkreldis.2016.11.017","volume":"33","author":"R Bhidayasiri","year":"2016","unstructured":"Bhidayasiri R, Ruiz PJG, Henriksen T. Practical management of adverse events related to apomorphine therapy. Park Relat Disord. 2016;33:S42\u20138. https:\/\/doi.org\/10.1016\/j.parkreldis.2016.11.017.","journal-title":"Park Relat Disord"},{"key":"948_CR38","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/970534","volume":"2015","author":"K Horv\u00e1th","year":"2015","unstructured":"Horv\u00e1th K, Aschermann Z, \u00c1cs P, Deli G, Janszky J, Komoly S, et al. Minimal clinically important difference on Parkinson\u2019s disease sleep scale 2nd version. Parkinsons Dis. 2015;2015:970534. https:\/\/doi.org\/10.1155\/2015\/970534.","journal-title":"Parkinsons Dis"},{"key":"948_CR39","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1080\/09638288.2022.2074152","volume":"45","author":"G Taghizadeh","year":"2023","unstructured":"Taghizadeh G, Fereshtehnejad S-M, Goudarzi S, Jamali S, Mehdizadeh M. Minimal clinically important difference of the King\u2019s Parkinson\u2019s Disease Pain Scale. Disabil Rehabil. 2023;45:1680\u20133. https:\/\/doi.org\/10.1080\/09638288.2022.2074152.","journal-title":"Disabil Rehabil"},{"key":"948_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000455863","volume":"48","author":"K Horv\u00e1th","year":"2017","unstructured":"Horv\u00e1th K, Aschermann Z, Kov\u00e1cs M, Makkos A, Harmat M, Janszky J, et al. Changes in quality of life in Parkinson\u2019s Disease: how large must they be to be relevant? Neuroepidemiology. 2017;48:1\u20138. https:\/\/doi.org\/10.1159\/000455863.","journal-title":"Neuroepidemiology"},{"key":"948_CR41","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1001\/jama.2024.25056","volume":"333","author":"DB Reuben","year":"2025","unstructured":"Reuben DB, Gill TM, Stevens A, Williamson J, Volpi E, Lichtenstein M, et al. Health system, community-based, or usual dementia care for persons with dementia and caregivers. JAMA. 2025;333:950\u201361. https:\/\/doi.org\/10.1001\/jama.2024.25056.","journal-title":"JAMA"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00948-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00948-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00948-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:11:36Z","timestamp":1784819496000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00948-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["948"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00948-6","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"27 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Financial arrangements of the authors with companies whose products may be related to the present report are listed as declared by the authors: Wolfgang H. Jost serves as an advisor and speaker for AbbVie, Bial, Desitin, Stada, UCB, and Zambon. Filip Bergquist has received advisory and lecture fees from AbbVie and research support in kind from Global Kinetics Corporation. Andrew Evans has received honoraria AbbVie, Abbott, STADA, Pfizer, Ipsen, Encapsulate, Seqirus, Bluerock for presentations, grant support from the Michael J. Fox Foundation, the National Health and Medical Research Council, and has been a\u00a0scientific advisory board member for AbbVie and STADA. Sharon Hassin-Baer is a study investigator and an advisor for AbbVie; has received funding\/grant support from AbbVie; speaker honoraria from AbbVie, Medison, and Allergan; has received consultancy fees from Neuroderm, Takeda, and Teva; and has received\u00a0advisory fees from Teva and AbbVie. Robert A. Hauser has received speaking fees from Abbvie, Amneal Pharmaceuticals, Kyowa Kirin, Neurocrine Biosciences, and Supernus; has received consulting fees from Abbvie, ABLi Therapeutics, Amneal, Biogen, Cerevance, Cerevel, Clario, Forsee Pharmaceuticals, HanAll Biopharma, Inhibikase, Intrance (PSG), Kiefe RX, Kyowa Kirin, Mitsubishi Tanabe, Nano PharmaSolutions, Neurocrine, Neuroderm, NDP Pharmaceuticals, Photopharmics, Regenxbio, Revance, Serina Therapeutics, Stoparkinson, Sumitomo, Supernus, Theravance, Truebinding, UCB, and Zambon; serves on a scientific advisory board for Stoparkinson, Inhibikase, and PhotoPharmics; has stock options in Enterin, Inhibikase, and Axial Therapeutics; has received intellectual property interests from a PD Diary through his University; acknowledges a Center of Excellence grant from the Parkinson Foundation; and Robert\u00a0A.\u00a0Hauser\u2019s University has received research support from Abbvie, Inc., Amneal Pharmaceuticals, Annovis Bio Inc, Biogen MA, Inc., Cavion, Inc., Cerevance Beta, Inc., Cerevel Therapeutics, Enterin, F. Hoffman La Roche Ltd, Genentech, Inc., Global Kinetics Corporation, Inhibikase Therapeutics, Michael J Fox Foundation, Motric Bio, Inc., NeuroDerm Ltd, Sage Therapeutics, Scion NeuroStim, Sun Pharma Advanced Research Company, Ltd., Teva Branded Pharmaceuticals, Truebinding, Inc., UCB, and\u00a0UCB Biopharma SRL. Tove Henriksen has served as a speaker for AbbVie, Britannia, Convatec, Ipsen, Lundbeck, Neuoderm, and Nordic Infucare; is a primary investigator for the M15\u2014741 and M15\u2014737 studies and a study sponsored by Britannia; and is a board member of a data monitoring committee for a Lundbeck-sponsored study. Irene A. Malaty has participated in research funded by AbbVie, Aevum, Dystonia Coalition, Emalex, Neuroderm, Parkinson Foundation, Praxis, Revance, and Sage but has no owner interest in any pharmaceutical company; has received consulting fees from AbbVie and Aevum; has received travel compensation or honoraria from Medscape, Parkinson Study Group, and Parkinson Foundation; and has received\u00a0royalties from Robert Rose Publishers. Tiago A. Mestre has received research support from the Canadian Institutes of Health Research, the Ontario Research Fund, Michael J Fox Foundation, Parkinson Canada, University of Ottawa\/Parkinson Research Consortium, Weston Brain Foundation; has received personal compensation as\u00a0a consultant for AbbVie, CHDI, Sunovion, Valeo Pharma, Roche, Biogen, nQ Medical; and has received personal compensation as honoraria and for speakers bureau for AbbVie, Valeo Pharma. Pablo Mir has received financial support from the Spanish Ministry of Science and Innovation, the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional, Consejer\u00eda de Econom\u00eda, Innovaci\u00f3n, Ciencia y Empleo de la Junta de Andaluc\u00eda, the Consejer\u00eda de Salud y Bienestar Social de la Junta de Andaluc\u00eda the Consejer\u00eda de Transformaci\u00f3n Econ\u00f3mica, Industria, Conocimiento y Universidades de la Junta de Andaluc\u00eda; and has received support for attending meetings and\/or travel or honorarium for lecturing from Abbott, Allergan, AbbVie, Bial, Britannia, Italfarmaco, Merz, UCB, Teva, and Zambon. Ramon Rodriguez has been a consultant and\/or speaker for AbbVie, Eisai, Teva, Neurocrine, Kyowa Kirin, and has received research support from Cerevel, Cerevance, Teva, Neurocrine, CND Life Sciences, Eli Lilly, Eisai, Biogen, Neuroderm, MTPA, Koneksa, ACR, and Teva. Petra Schwingenschuh has received consulting and speaking honoraria from AbbVie, Bial, BostonScientific, Merz, and Stada; has served as an investigator in clinical trials sponsored by AbbVie, Britannia, Roche, and Takeda; reports grants from the FWF Austrian Science Fund; and is a member of the MDS Clinical Neurophysiology and Tremor Study Groups. Mihaela Simu has received honoraria for lectures at symposia and consultant fees from AbbVie, AOP Orphan, BI, KRKA, Merck, Novartis, Roche, Sanofi, Servier, Teva, and UCB. Lars Bergmann, Teresa T. Zhou, Sarah Caughlin, Mallika Gopalkrishnan, Pavnit Kukreja, Marie O\u2019Meara, Juan Carlos Parra, and Megha B. Shah are employees of AbbVie and may own stocks\/shares in the company. Jason Aldred is a study investigator for AbbVie, AC Immune, Annovis, Aptinyx, AstraZeneca, Atara, Athira, Biogen, Biovie, Boston Scientific, Celgene, Cerevance, Cerevel, Denali, EIP, Eli Lilly, Impax, Inhibikase, IRL Therapeutics, Merz, Neuraly, Neurocrine, Neuoderm, Novartis, PD Gene\/PSG, Praxis, Revance, Roche\/Genentech, Sage, Sanofi\/Genzyme, Scion Neurostem, Takeda, Theravance, Triplet\/HSG, and UCB, and has received honorarium from Abbott, AbbVie, Allergan (now AbbVie), Boston Scientific, Medtronic, Teva, and US World Meds.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is approved by all global institutions and conducted in accordance with Advarra (central institutional review board; reference number: 00023875); Ethics (Helsinki) Committee at the Sheba Medical Center (0660\u201423-SMC); Ethics Committee for Investigation with Medicinal Products at Puerta de Hierro Majadahonda University Hospital (178\/23); Ethics Committee of the Medical University of Graz (36\u2014261 ex 23\/24); Ethics Committee of the State Medical Association of Baden-W\u00fcrttemberg, Stuttgart (B-F-2023\u2014115); Institutional Review Board (00005790); Ottawa Health Science Network Research Ethics Board (20240555\u201401H) Royal Melbourne Hospital Human Research Ethics Committee (HREC\/103037\/MH-2023); Scientific Ethics Committee (none available); and Swedish Ethical Review Board (2023\u201406693\u201401) guidelines. Documentation of ethics approval from each country, and their respective institutions, can be found in Supplementary Material 2. Patients consented to fully comply with study-related procedures and prior to their initiation, each patient or legal authorized representative voluntarily signed an Authorization for Use\/Disclosure of Data informed consent form according to national regulations after the study was explained and patients\u2019 questions were answered.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Wolfgang H. Jost, Filip Bergquist, Andrew Evans, Sharon Hassin-Baer, Robert A. Hauser, Tove Henriksen, Irene A. Malaty, Tiago A. Mestre, Pablo Mir, Ramon Rodriguez, Petra Schwingenschuh, Mihaela Simu, and Jason Aldred were study investigators.","order":3,"name":"Ethics","label":"Investigators","group":{"name":"EthicsHeading","label":"Declarations"}}]}}